Connect with us
The performance of the pharmaceutical sector in the third quarter was worse than that of the Ibex35, the Spanish benchmark index, which fell by 0.3% in...
Grifols has assured that 87.93% of bondholders of its secured bonds, 81.01% of unsecured bonds, the required 93.82% of underwriters of its syndicated credit facility, and...
Grifols increases its profits in the first six months of the year. The Spanish multinational, which specializes in the production of plasma derivatives, achieved a profit...
The total economic impact of Grifols in the main countries where it operates is estimated at $8.85 billion (€7.5 billion) and 140,000 jobs generated, including direct,...
This past year was not a good one for the Spanish pharmaceutical sector. According to a calculation, the six listed companies on the continuous market has...
Grifols' gross operating profit (Ebitda) was $356.4 million (€296.8 million) compared to $421 million (€351 million) in the first quarter of 2020 and accounted for 25.1%...
The Spanish pharma sector increased 5% on the stock market in the first quarter despite the fall of Grifols. Pharma Mar was the pharmaceutical company with...
The Spanish company will supply plasma to the Regional Center for Hemodonation of the Region of Murcia (CRH) for two years.Under the contract, Grifols will distribute...
Grifols, a company that specializes in the production of plasma derivatives, will supply the Catalan Institute of Health (ICS) with 500,000 rapid tests for detecting COVID-19....
The European stock markets are starting yet another long week full of uncertainties. However, the main European places loosened at the close of the session showing...